Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
What the film says
When glioblastoma comes back, engineered immune cells are among the few new ideas, but two things hold them back: the tumor switches them off, and no one knows the best way in.
The idea: build a natural killer cell that resists the tumor's defenses, and test three routes head to head.
At MD Anderson, donor natural killer cells receive receptors for two glioblastoma markers, IL13Rα2 and EGFRvIII. They secrete interleukin-21 to sustain themselves, and two genes are deleted, the TGF-beta receptor and the steroid receptor, so neither the tumor nor patients' steroids can quiet them. Cells go into the tumor, the ventricles, or an artery; tissue is studied afterward to see which route works best.
Chibawanye Ene leads it. Public record; not medical advice.
Sources behind this film
Recurrent GBM; prior radiation and temozolomide; Dual CAR IL13Rα2 + EGFRvIII; IL-21 secretion; TGF-βR2 and NR3C1 deletions; NR3C1 = glucocorticoid receptor → steroid resistance; Three routes: intra-tumoral, intra-ventricular (Ommaya), intra-arterial; window-of-opportunity design comparing persistence and function in post-treatment specimens (+1 more lines)
The drug
Primary Objectives 1. To undertake a window of opportunity (WOO) clinical trial to compare the biological endpoints of Dual CAR Dual KO NK cells persistence, immunological phenotype and anti-tumor function after administration of Dual CAR Dual KO NK cells via 3 different routes: intra-tumoral, intra-ventricular or intra-arterial injection. By quantitatively assessing post-treatment specimens, the trial will determine the optimal route of administration of this agent. 2.
To assess the safety of Dual CAR Dual KO NK cells after administration via 3 different routes: intra-tumoral, intra-ventricular or intra-arterial injection. Secondary Objectives 1. To determine response as measured by Response Assessment in Neuro-Oncology (RANO), progression free survival (PFS), time to progression (TTP), and overall survival (OS). 2.
The study
To find the best method of administering NK cells in patients with recurrent glioblastoma.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.